Search results
Showing 1 to 11 of 11 results for tirzepatide
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]
Awaiting development [GID-TA11700] Expected publication date: TBC
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
In development [GID-TA11104] Expected publication date: TBC
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
New treatment option recommended for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use